Optical Coherence Tomography Structural Abnormality Detection in Glaucoma Using Topographically Correspondent Rim and Retinal Nerve Fiber Layer Criteria.
Adolescent
Adult
Aged
Aged, 80 and over
Cross-Sectional Studies
Female
Glaucoma, Open-Angle
/ diagnostic imaging
Humans
Intraocular Pressure
/ physiology
Male
Middle Aged
Nerve Fibers
/ pathology
Ocular Hypertension
/ diagnostic imaging
Optic Disk
/ diagnostic imaging
Optic Nerve Diseases
/ diagnostic imaging
ROC Curve
Retinal Ganglion Cells
/ pathology
Retrospective Studies
Sensitivity and Specificity
Tomography, Optical Coherence
Vision Disorders
/ physiopathology
Visual Fields
/ physiology
Young Adult
Journal
American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
12
09
2019
revised:
05
12
2019
accepted:
18
12
2019
pubmed:
4
1
2020
medline:
11
7
2020
entrez:
4
1
2020
Statut:
ppublish
Résumé
This study evaluated the ability of topographically correspondent (TC) minimum rim width (MRW) and peripapillary retinal nerve fiber layer thickness (pRNFLT) criteria to detect optical coherence tomography (OCT) structural abnormality in glaucoma (GL) and glaucoma suspect (GLS) eyes. Retrospective cross-sectional study. A total of 196 GL eyes, 150 GLS eyes, and 303 heathy eyes underwent pRNFL and 24 radial optic nerve head OCT imaging and manual correction of the internal limiting membrane, Bruch's membrane opening (BMO), and outer pRNFL segmentations. MRW and pRNFLT were quantified in 6 Garway-Heath or 12 30-degree (clock-hour) sectors. OCT abnormality for each parameter was defined to be less than the 5th percentile of the healthy eye distribution. OCT abnormality for individual eyes was defined using global, sectoral, and combined parameter criteria that achieved ≥95% specificity in the healthy eyes. TC combination criteria required the sectoral location of MRW and pRNFLT abnormality to be topographically aligned and included comMR (a previously reported TC combination consisting of MRW and pRNFLT parameter: [MRW + pRNFLT × (average MRW healthy eyes/average pRNFLT healthy eyes) MRW]. TC sectoral criteria (1 Garway-Heath MRW + corresponding Garway-Heath RNFLT), (one 30-degree MRW + any 1 corresponding or adjacent 30-degree pRNFLT), 30-degree and Garway-Heath comMR-TI and global comMR were the best performing criteria, demonstrating (96%-99% specificity), 86%-91% sensitivity for GL, 80%-84% sensitivity for early GL (MD ≥ -4.0 dB) and 93%-96% sensitivity for moderate-to-advanced GL (MD < -4.0 dB). Clinically intuitive TC MRW and pRNFLT combination criteria identified the sectoral location of OCT abnormality in GL eyes with high diagnostic precision.
Identifiants
pubmed: 31899204
pii: S0002-9394(19)30621-X
doi: 10.1016/j.ajo.2019.12.020
pmc: PMC7214190
mid: NIHMS1547852
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
203-216Subventions
Organisme : NEI NIH HHS
ID : R01 EY019674
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY020922
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY021281
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Références
Prog Retin Eye Res. 2017 Mar;57:46-75
pubmed: 28012881
Acta Ophthalmol. 2019 Mar;97(2):e207-e215
pubmed: 30338652
Am J Ophthalmol. 2003 Jun;135(6):838-43
pubmed: 12788124
Acta Ophthalmol Scand Suppl. 2002;236:34-6
pubmed: 12390129
Ophthalmology. 1979 Oct;86(10):1803-30
pubmed: 553256
Br J Ophthalmol. 2020 Feb;104(2):270-275
pubmed: 31147377
J Glaucoma. 2013 Jun-Jul;22(5):343-8
pubmed: 23719180
Invest Ophthalmol Vis Sci. 2012 Jun 14;53(7):3598-604
pubmed: 22570353
J Glaucoma. 2017 May;26(5):450-458
pubmed: 28234677
Ophthalmology. 2013 Mar;120(3):535-543
pubmed: 23265804
Ophthalmology. 1993 Jan;100(1):63-8
pubmed: 8433829
Am J Ophthalmol. 2017 Feb;174:1-8
pubmed: 27818206
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT575-84
pubmed: 27547890
Eye (Lond). 2018 Feb;32(2):314-323
pubmed: 29386616
Br J Ophthalmol. 2012 Dec;96(12):1452-5
pubmed: 23018425
Exp Eye Res. 2011 Aug;93(2):120-32
pubmed: 20849846
Invest Ophthalmol Vis Sci. 2014 Jan 29;55(1):612-24
pubmed: 24408977
Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6886-91
pubmed: 26501416
Ophthalmology. 2000 Oct;107(10):1809-15
pubmed: 11013178
Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):4194-204
pubmed: 27548890
Invest Ophthalmol Vis Sci. 2014 Mar 13;55(3):1531-9
pubmed: 24474264
Am J Ophthalmol. 2006 Oct;142(4):576-82
pubmed: 17011848
Invest Ophthalmol Vis Sci. 2014 Feb 03;55(2):632-49
pubmed: 24370831
Invest Ophthalmol Vis Sci. 2018 May 1;59(6):2357-2370
pubmed: 29847642
Graefes Arch Clin Exp Ophthalmol. 2011 Jul;249(7):1039-45
pubmed: 21240522
Ophthalmology. 2016 Jun;123(6):1201-10
pubmed: 27001534
Invest Ophthalmol Vis Sci. 2014 Nov 25;55(12):8343-8
pubmed: 25425301
Invest Ophthalmol Vis Sci. 2016 Jan 1;57(1):181-7
pubmed: 26795824
Ophthalmology. 2017 Sep;124(9):1392-1402
pubmed: 28461018
Ophthalmology. 2015 Dec;122(12):2392-8
pubmed: 26421707
Curr Opin Ophthalmol. 2014 Mar;25(2):104-11
pubmed: 24370973
Am J Ophthalmol. 2013 Aug;156(2):218-227.e2
pubmed: 23768651
Ophthalmology. 2016 Apr;123(4):760-70
pubmed: 26746597
Ophthalmology. 2017 Aug;124(8):1218-1228
pubmed: 28461015
Ophthalmology. 2003 Jan;110(1):177-89
pubmed: 12511364
Am J Ophthalmol. 2019 Mar;199:28-43
pubmed: 30414397
Invest Ophthalmol Vis Sci. 2011 Apr 22;52(5):2634-9
pubmed: 21282570
J Glaucoma. 2017 Jan;26(1):27-33
pubmed: 27636592
PLoS One. 2018 Dec 18;13(12):e0206887
pubmed: 30562371
Invest Ophthalmol Vis Sci. 2014 Nov 20;55(12):8428-38
pubmed: 25414193
J Ophthalmol. 2011;2011:914250
pubmed: 21052550
Ophthalmology. 2018 Nov;125(11):1710-1719
pubmed: 29887333
Ophthalmology. 2015 Sep;122(9):1786-94
pubmed: 26198806
Transl Vis Sci Technol. 2018 Aug 24;7(4):14
pubmed: 30159207
Arch Ophthalmol. 2009 Oct;127(10):1250-6
pubmed: 19822839
Ophthalmology. 2009 May;116(5):840-7
pubmed: 19410941
Am J Ophthalmol. 2019 Dec;208:94-102
pubmed: 31351051
Ophthalmology. 2012 Jun;119(6):1151-8
pubmed: 22365056
Ophthalmology. 2018 Jun;125(6):822-831
pubmed: 29433852
Arch Ophthalmol. 1982 Jan;100(1):135-46
pubmed: 7055464
Invest Ophthalmol Vis Sci. 2017 Aug 1;58(10):4106-4113
pubmed: 28828482
Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6788-95
pubmed: 26567791
Ophthalmology. 2016 Jun;123(6):1181-9
pubmed: 26992843
J Glaucoma. 2012 Sep;21(7):498-504
pubmed: 21637115
Arch Ophthalmol. 1991 Jan;109(1):77-83
pubmed: 1987954
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Ophthalmology. 2008 Jun;115(6):949-56
pubmed: 17981334
Invest Ophthalmol Vis Sci. 2019 Feb 1;60(2):795-806
pubmed: 30811523
Invest Ophthalmol Vis Sci. 2014 Dec 11;56(1):98-105
pubmed: 25503459
Invest Ophthalmol Vis Sci. 2011 Aug 22;52(9):6651-61
pubmed: 21730343
J Glaucoma. 2019 May;28(5):368-374
pubmed: 30855415
PLoS One. 2014 Mar 18;9(3):e92225
pubmed: 24643069
Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5062-70
pubmed: 20463326
Arch Ophthalmol. 2009 Dec;127(12):1603-9
pubmed: 20008715
Ophthalmology. 2014 Jan;121(1):100-109
pubmed: 23948465
Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6208-16
pubmed: 26426403